Cencora, Inc. (NYSE:COR) Shares Sold by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC lessened its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 37.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,619 shares of the company's stock after selling 3,350 shares during the quarter. Integrated Wealth Concepts LLC's holdings in Cencora were worth $1,263,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. JFS Wealth Advisors LLC boosted its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in Cencora in the fourth quarter valued at $30,000. Kentucky Trust Co bought a new stake in shares of Cencora in the 4th quarter worth approximately $33,000. Householder Group Estate & Retirement Specialist LLC boosted its holdings in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares during the period. Finally, WASHINGTON TRUST Co increased its position in shares of Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after acquiring an additional 46 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on COR shares. Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday, April 15th. Bank of America lifted their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. UBS Group increased their price objective on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday. JPMorgan Chase & Co. raised their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Finally, Wells Fargo & Company increased their price target on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Cencora has a consensus rating of "Moderate Buy" and a consensus price target of $290.00.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the sale, the chairman now directly owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This represents a 4.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock valued at $13,580,967 in the last three months. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Performance

COR stock traded up $1.74 during midday trading on Friday, reaching $292.17. The stock had a trading volume of 1,046,574 shares, compared to its average volume of 1,511,470. The stock has a market cap of $56.66 billion, a PE ratio of 41.56, a P/E/G ratio of 1.31 and a beta of 0.55. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $296.65. The firm has a fifty day simple moving average of $272.65 and a two-hundred day simple moving average of $251.43. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.75%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.